Senores Pharmaceuticals reported a strong performance for the quarter ended March 2026, with both revenue and profitability witnessing sharp year-on-year (YoY) growth driven by robust operational performance.
The company posted a consolidated net profit of ₹36.67 crore in Q4 FY26, marking a surge of nearly 104% compared to ₹17.97 crore reported in the corresponding quarter last year.
Revenue from operations during the quarter stood at ₹175.19 crore, up 53.4% YoY from ₹114.21 crore in Q4 FY25.
Total income for the quarter increased to ₹192.86 crore against ₹125.98 crore in the year-ago period, reflecting a growth of 53.1%.
Senores Pharmaceuticals Q4 FY26 Key Highlights
- Revenue from operations rose 53.4% YoY to ₹175.19 crore from ₹114.21 crore
- Total income increased 53.1% YoY to ₹192.86 crore from ₹125.98 crore
- Profit before tax (PBT) jumped 129.4% YoY to ₹47.40 crore from ₹20.68 crore
- Net profit surged 104.1% YoY to ₹36.67 crore from ₹17.97 crore
- Total expenses stood at ₹145.46 crore compared to ₹105.30 crore in Q4 FY25
The sharp rise in profitability was supported by healthy revenue growth and improved operating leverage during the quarter.
Full-Year FY26 Performance
For the financial year ended March 2026, Senores Pharmaceuticals reported consolidated revenue from operations of ₹632.63 crore, compared to ₹398.25 crore in FY25, registering a growth of 58.8%.
Net profit for FY26 stood at ₹121.53 crore, more than doubling from ₹58.34 crore reported in the previous financial year.
Profit before tax for the year surged to ₹159.10 crore from ₹70.57 crore in FY25, reflecting strong earnings momentum.